Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 2, 2003, Pages 139-146

  Musser, Steven M ^a   Egorin, Merrill J ^b,c   Zuhowski, Eleanor G ^b   Hamburger, Deborah R ^b   Parise, Robert A ^b   Covey, Joseph M ^d   White, Kevin D ^a   Eiseman, Julie L ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ansamycin; Biliary excretion; Geldanamycin; HSP90

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; BENZOQUINONE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A; DRUG METABOLITE; EPOXIDE; EPOXIDE HYDROLASE; GELDANAMYCIN; NSC 707545; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; HUMANS; LACTAMS, MACROCYCLIC; MALE; MASS SPECTROMETRY; OXIDATION-REDUCTION; RATS; RATS, INBRED F344; RIFABUTIN;

EID: 0041375547     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0630-z     Document Type: Article

References (44)

1. Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH (2001) Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237
2. An WG, Schnur RC, Neckers L, Blagosklonny MV (1997) Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 40:60
3. An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-ab1 and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355
4. Bamberger CM, Wald M, Bamberger AM, Schulte HM (1997) Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin. Mol Cell Endocrinol 131:233
5. Banerji U, O'Donnel A, Scurr M, Benson C, Brock C, Hanwell J, Stapleton S, Raynaud F, Simmons L, Turner A, Walton M, Workman P, Judson I (2002) A pharmacokinetically (PK)-pharmacodyamically (PD) driven phase I trial of the HSP90 molecular chaperone inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG). Proc Am Assoc Cancer Res 43:272
6. Blagosklonny MV (2002) Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16:455
7. Blagosklonny MV, Toretsky J, Neckers L (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933
8. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L (1996) p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 271:4974
9. Chen EX, Bies R, Ramanthan RK, Zuhowski EG, Trump DL, Egorin MJ (2003) Population pharmacokinetic (PK) analysis of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 484:122a
10. Chiosis G, Rosen N, Sepp-Lorenzino L (2001) LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett 11:909
11. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442
12. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385
13. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291
14. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7
15. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843
16. Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID (1997) Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer 70:221
17. Kasuya Y, Lu Z, Kopeckova P, Kopecek J (2001) Improved synthesis and evaluation of 17-substituted aminoalkylgeldanamycin derivatives applicable to drug delivery systems. Bioorg Med Chem Lett 11:2089
18. Kim S, Kang J, Hu W, Evers BM, Chung DH (2003) Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 103:352
19. Kuduk SD, Zheng FF, Sepp-Lorenzino L, Rosen N, Danishefsky SJ (1999) Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett 9:1233
20. Kuduk SD, Harris TC, Zheng FF, Sepp-Lorenzino L, Ouerfelli Q, Rosen N, Danishefsky SJ (2000) Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg Med Chem Lett 10:1303
21. Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA (2000) Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 92:1573
22. McIlwrath AJ, Brunton VG, Brown R (1996) Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother Pharmacol 37:423
23. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD (1994) Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 54:2724
24. Miller P, Schnur RC, Barbacci E, Moyer MP, Moyer JD (1994) Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem Biophys Res Commun 201:1313
25. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796
26. Munster PN, Tong W, Schwartz L, Larson S, Kenneson K, De La Cruz A, Rosen N, Scher H (2001) Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (Pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 20:83a
27. Neckers L, Schulte TW, Mimnaugh E (1999) Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 17:361
28. Nimmanapalli R, O'Bryan E, Bhalla K (2001) Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61:1799
29. Sakagami M, Morrison P, Welch WJ (1999) Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones 4:19
30. Sasaki K, Yasuda H, Onodera K (1979) Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J Antibiot (Tokyo) 32:849
31. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, DiOrio CI, Barbacci EG, Miller PE, et al (1995) erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 38:3813
32. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38:3806
33. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273
34. Schulte TW, Blagosklonny MV, Ingui C, Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585
35. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, et al (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies (conference report). Eur J Drug Metab Pharmacokinet 16:249
36. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2002) 17-DMAG (NSC 07545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG. Euro J Cancer 38 [Suppl 7]:60
37. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986
38. Srethapakdi M, Liu F, Tavorath R, Rosen N (2000) Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 60:3940
39. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239
40. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305
41. Whitesell L, Cook P (1996) Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 10:705
42. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324
43. Wilson RH, Takimoto CH, Agnew EB, Morrison G, Grollman F, Thomas RR, Saif MW, Hopkins J, Allegra C, Grochow L, Szabo E, Hamilton JM, Monahan BP, Neckers L, Grem JL (2001) Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:82a
44. Zheng FF, Kuduk SD, Chiosis G, Munster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N (2000) Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res 60:2090